Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001086293 | SCV000544305 | benign | Tuberous sclerosis 2 | 2023-12-07 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000713932 | SCV000844579 | uncertain significance | not provided | 2017-11-20 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000713932 | SCV001795460 | likely benign | not provided | 2021-07-21 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001086293 | SCV002039825 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002257693 | SCV002533499 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-07-27 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002257693 | SCV002626522 | likely benign | Hereditary cancer-predisposing syndrome | 2021-12-01 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |